Sector News

Ventus sells its lead drug candidate to Novo Nordisk

October 2, 2022
Life sciences

Biotechnology startup Ventus Therapeutics is licensing its lead research program, a drug candidate for inflammatory disorders, to Novo Nordisk in exchange for $70 million.

The experimental drug, dubbed VENT-01, is a small molecule that targets inflammasomes, which are protein complexes in immune system cells that activate inflammatory responses.

Though it was a difficult decision to part with Ventus’ lead program, company CEO Marcelo Bigal said the turbulent stock market contributed to the decision to partner with Novo.

“Without Novo, we were funded to bring three programs to the clinic, but with Novo we’re now funded to bring the programs into Phase 2, which means we’re funded into 2025,” Bigal said in an interview.

An inflammasome known as NLRP3 is the focus of Ventus’ experimental treatment. NLRP3 is implicated in a wide range of diseases including Alzheimer’s, Parkinson’s, Type 2 diabetes, intestinal cancer and fatty liver disorders.

Novo will develop VENT-01 for use in nonalcoholic steatohepatitis, chronic kidney disease and other cardiometabolic disorders — areas in which the Danish drugmaker has experience developing medicines. READ MORE

by Gwendolyn Wu


comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.